Response status after R-MPV and following transplant
| . | CR/CRu . | PR . | SD . | PD . |
|---|---|---|---|---|
| Response after 5 R-MPV cycles (N = 32) | 14 (44%) | 16 (50%) | 1* (3%) | 1 (3%) |
| Best response to R-MPV induction chemotherapy (5 or 7 cycles) (N = 32) | 21 (66%) | 9 (28%) | 1* (3%) | 1 (3%) |
| Pretransplant response status in the transplanted patients (N = 26) | 18 (69%) | 7 (27%) | 1* (4%) | 0 (0) |
| Best response after transplant (N = 26) | 21 (81%) | 3 (11%) | 1* (4%) | 1 (4%) |
| . | CR/CRu . | PR . | SD . | PD . |
|---|---|---|---|---|
| Response after 5 R-MPV cycles (N = 32) | 14 (44%) | 16 (50%) | 1* (3%) | 1 (3%) |
| Best response to R-MPV induction chemotherapy (5 or 7 cycles) (N = 32) | 21 (66%) | 9 (28%) | 1* (3%) | 1 (3%) |
| Pretransplant response status in the transplanted patients (N = 26) | 18 (69%) | 7 (27%) | 1* (4%) | 0 (0) |
| Best response after transplant (N = 26) | 21 (81%) | 3 (11%) | 1* (4%) | 1 (4%) |
This 1 patient had no measurable disease at start of R-MPV because of complete resection, remained stable after 7 cycles of R-MPV and underwent HDC-ASCT, and was considered nonevaluable for objective response rate assessment.